{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:57:14Z","timestamp":1791824234921,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["52402118"],"award-info":[{"award-number":["52402118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05936-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:11:24Z","timestamp":1751386284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vitro evaluation of mesalazine enteric-coated tablet dissolution by the reciprocating cylinder method"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinxiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaihua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5936_CR1","first-page":"934","volume":"16\/074","author":"W Garrett","year":"2019","unstructured":"Garrett, W. & Howitt, M. Methods of treating inflammatory bowel disease and parasite infection. U S Patent Application No. 16\/074, 934 (2019).","journal-title":"U S Patent Application No"},{"key":"5936_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","volume":"353","author":"E Laura","year":"2023","unstructured":"Laura, E., McCoubrey, A. & Favaron Atheer Awad J. Journal Controlled Release 3531107\u20131126 (2023).","journal-title":"Atheer Awad J. Journal Controlled Release"},{"key":"5936_CR3","doi-asserted-by":"crossref","unstructured":"Desai, S. A. & Kale, R. Method development and validation of mesalazine in pharmaceutical dosage form: a review. Int J. Pharma Biol. Sci. Arch 7(3), 105\u2013108 (2019).","DOI":"10.32553\/ijpba.v7i3.130"},{"issue":"3","key":"5936_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3329\/icpj.v2i3.13577","volume":"2","author":"S Badhana","year":"2013","unstructured":"Badhana, S., Garud, N. & Garud, A. Colon specific drug delivery of mesalazine using Eudragit S100-coated Chitosan microspheres for the treatment of ulcerative colitis. Int. J. Curr. Pharma. 2(3), 42\u201348 (2013).","journal-title":"Int. J. Curr. Pharma"},{"issue":"3","key":"5936_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.gtc.2010.08.011","volume":"39","author":"I Sonu","year":"2010","unstructured":"Sonu, I., Lin, M. V., Blonski, W. & Lichtenstein, G. R. Clinical Pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol. Clin. 39(3), 559\u2013599 (2010).","journal-title":"Gastroenterol. Clin."},{"issue":"3","key":"5936_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.7326\/0003-4819-101-3-377","volume":"101","author":"MA Peppercorn","year":"1984","unstructured":"Peppercorn, M. A. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann. Intern. Med. 101(3), 377\u2013386 (1984).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"5936_CR7","first-page":"1","volume":"45","author":"Lun Gen Lu","year":"2022","unstructured":"Lun Gen Lu. Boshen digestive system diseases. J. Journal Southwest. Med. University. 45(1), 1\u20136 (2022).","journal-title":"J. Journal Southwest. Med. University"},{"key":"5936_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12325-015-0206-4","volume":"32","author":"A Abinusawa","year":"2015","unstructured":"Abinusawa, A. & Tenjarla, S. Release of 5-Aminosalicylic Acid(5-ASA)from mesalazine formulations at various pH. Levels Adv Ther. 32, 477\u2013484 (2015).","journal-title":"Levels Adv Ther"},{"issue":"10","key":"5936_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2174\/1567201818666210708121739","volume":"18","author":"M Shaikh","year":"2021","unstructured":"Shaikh, M., Neha, N. & Desai Munira Momin and Lokesh Kumar bhatt.j. Curr. Drug Deliv. 18(10), 1563\u20131573 (2021).","journal-title":"Curr. Drug Deliv."},{"key":"5936_CR10","unstructured":"FDA website. Drug Database, Dissolution Methods, Search Results for Mesalazinehttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/dsp_SearchResults.cfm"},{"key":"5936_CR11","unstructured":"Fu Ying Li. Wen Di Dong. Liu Yun. Consistency of in vitro release curves between generic mesalazine enteric-coated Tablets and reference listed drug SALOFALK \u00ae.J. Chin Mod. Drug Appl. 16 No 15, 186\u2013190 (2022)."},{"key":"5936_CR12","unstructured":"Tang Xing. Edited. Oral Sustained-release and Extend-release Formulation292 (People\u2019s Medical Publishing Pres, 2007)."},{"key":"5936_CR13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5958\/2231-5691.2020.00014.3","volume":"10","author":"P Terse","year":"2020","unstructured":"Terse, P. & Mallya, R. Formulation and evaluation of celecoxib loaded colon targeted microsponges. Asian J. Res. Pharm. Sci. 10, 73 (2020).","journal-title":"Asian J. Res. Pharm. Sci."},{"issue":"6","key":"5936_CR14","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.xphs.2018.02.016","volume":"06","author":"Frank Karkossa","year":"2018","unstructured":"Frank Karkossa Sanara klein.a. J. J. Pharm. Sci. 06(6), 1680\u20131689 (2018).","journal-title":"J. Pharm. Sci."},{"key":"5936_CR15","doi-asserted-by":"publisher","unstructured":"USP. United States Pharmacopeia[S]. Chapter 1092.USP Currently Official USPNF 2021 Issue 1. https:\/\/doi.org\/10.31003\/USPNF_M643_05_01","DOI":"10.31003\/USPNF_M643_05_01"},{"key":"5936_CR16","unstructured":"Mesalazine Enteric-Coated Tablet Imported Specification, Beijing: CDE. 473. (2018)."},{"key":"5936_CR17","doi-asserted-by":"publisher","unstructured":"USP. United States Pharmacopeia[S]. Chapter BUFFER SOLUTIONS currently offical as of 01-May \u2013\u20092018. Volume No PF 43(1). https:\/\/doi.org\/10.31003\/USPNF_R2999_03_01","DOI":"10.31003\/USPNF_R2999_03_01"},{"key":"5936_CR18","unstructured":"ICH Q2(R1. ) Validation of analytical procedures: Text and methodology(Q2)R1."},{"key":"5936_CR19","doi-asserted-by":"publisher","unstructured":"USP. United States Pharmacopeia. Chapter 711, Currently Official on 01-May-2023. https:\/\/doi.org\/10.31003\/USPNF_M99470_03_01","DOI":"10.31003\/USPNF_M99470_03_01"},{"issue":"66","key":"5936_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejps.2014.10.002","volume":"01","author":"F Xie","year":"2015","unstructured":"Xie, F. & Ji, S. Zeneng cheng. In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. J. European J. Pharm. Sciences. 01(66), 163\u2013172 (2015).","journal-title":"J. European J. Pharm. Sciences"},{"key":"5936_CR21","doi-asserted-by":"publisher","unstructured":"USP. United States Pharmacopeia. Chapter 1236. Currently Official on 01-Aug-2024. https:\/\/doi.org\/10.31003\/USPNF_M2248_04_01","DOI":"10.31003\/USPNF_M2248_04_01"},{"key":"5936_CR22","unstructured":"FDA, Guidence for Insdustry Extended Release Oral Dosage Forms. Development, Evaluation, and Application of in Vitro\/in Vivo Correlations, accessed at: (1997). https:\/\/www.gmp-compliance.org\/files\/guidemgr\/1306fnl.pdf("},{"key":"5936_CR23","unstructured":"EMA. Guideline on the investigation of Bioequivalence, accessed at: (2010). https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-revl_en.pdf."},{"key":"5936_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2017.02.029","volume":"102","author":"MA Nguyen","year":"2017","unstructured":"Nguyen, M. A. et al. A survey on IVIVC\/IVIVR development in the pharmaceutical industry\u2014Past experience and current perspectives. Eur. J. Pharm. Sci. 102, 1\u201313 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"5936_CR25","unstructured":"Salofalk\u00ae, M. Enteric-Coated Tablets Instructions for Use, Approved by CDE on: 2008.07.08, Revised on: 2017.12.20."},{"key":"5936_CR26","doi-asserted-by":"crossref","unstructured":"Bott*, C. & Rudolph, W. Schneider. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system.j. Aliment. Pharmacol. Ther. 20, 347\u2013353 (2004).","DOI":"10.1111\/j.1365-2036.2004.02033.x"},{"key":"5936_CR27","doi-asserted-by":"crossref","unstructured":"Davan\u00e7o, M. G. Campos, D. R. & Carvalho, P. d. O. In Vitro-In vivo correlation in the development of oral drug formulation:a screen of the last two decades. J. International J. Pharmaceuticals 580, 119210 (2020).","DOI":"10.1016\/j.ijpharm.2020.119210"},{"key":"5936_CR28","doi-asserted-by":"publisher","unstructured":"Sandra Klein, Markus, W. Sep Rudolph, Brigitte skalsky. Use of the BioDis to generate a physiologically relevant IVIVC.J. Journal of controlled release. 3(130):216\u2013219. (2008). https:\/\/doi.org\/10.1016\/j.jconrel.2008.06.014","DOI":"10.1016\/j.jconrel.2008.06.014"},{"key":"5936_CR29","doi-asserted-by":"publisher","unstructured":"Cord, J. & Andreas, Y. C. Chen Consantinos Markopoulos. In vitro biorelevant models for evaluating modified release Mesalazine products to forecast the effect of formulation and meal intake on drug release. J. European journal of Pharmaceutics and biopharmaceutics. Volume 97, part A, Novermber Pages 39\u201350. (2015). https:\/\/doi.org\/10.1016\/j.ejpb.2015.09.002","DOI":"10.1016\/j.ejpb.2015.09.002"},{"issue":"1","key":"5936_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/CPDD.696","volume":"9","author":"S Zhang","year":"2020","unstructured":"Zhang, S. YaoLi,Shan-shan wei. Effects of differential food patterns on the pharmacokinetics of Enteric-Coated mesalazine tablets in the same cohort of healthy Chinese volunteers. J Clin. Pharmacol. Drug Development. 9(1), 41\u201349. https:\/\/doi.org\/10.1002\/CPDD.696 (2020).","journal-title":"J Clin. Pharmacol. Drug Development"},{"key":"5936_CR31","unstructured":"International conference on harmonization of technical requirements for registration. of pharmaceuticals for human use,ICH Harmonized Tripartite Guideline Pharmaceutical Development Q8(R2). Current Step 4 version, August (2009)."},{"key":"5936_CR32","doi-asserted-by":"publisher","unstructured":"Aykut Elmas, G. & Aky\u00fcz, A. Bergal. Mathematical modelling of drug release. J. Res. Eng. struct. Mater.,;6(4):327\u2013350. (2020). https:\/\/doi.org\/10.17515\/resm2020.178na0122","DOI":"10.17515\/resm2020.178na0122"},{"key":"5936_CR33","doi-asserted-by":"crossref","unstructured":"Sagar, D. May. Kadam1, Shashikant Dhole 2, Sohan chitlange. Formulation and evaluation of sustained release Colon targeted Mesalamine tablet. J. Research Pharm. Tech 13(5), 2241\u20132245.(2020).","DOI":"10.5958\/0974-360X.2020.00403.5"},{"key":"5936_CR34","doi-asserted-by":"crossref","unstructured":"Peppas & NA A model of dissolution controlled solute release from porous drug delivery polymeric systems. J. Biomed. Mater. Res. 6, 171079\u2013171087 (1983).","DOI":"10.1002\/jbm.820170615"},{"key":"5936_CR35","unstructured":"Pharmacopoeia of the People\u2019s Republic of China. Part4 General Chap. 9013, Sustained-release, Controlled-release and Delayed-release Formulation Guidelines (China Medical Science and Technology, 2025). ,2025.03."},{"issue":"5","key":"5936_CR36","first-page":"35","volume":"2","author":"JB Sharma Madhu","year":"2012","unstructured":"Sharma Madhu, J. B., Monika, G. & Manish Formulation and evaluation of colon targeted tablets of mesalazine. J. J. Drug Delivery &Therapeutics. 2(5), 35 (2012).","journal-title":"J. Drug Delivery &Therapeutics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05936-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:11:28Z","timestamp":1751386288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05936-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05936-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22066"}}